Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Trial Profile

Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium; Warfarin
  • Indications Atrial fibrillation; Decompensated heart failure
  • Focus Biomarker; Therapeutic Use
  • Acronyms ROAD HF-AF
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top